Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Rice-Made blood protein under Real-World watch for emergency patients

NCT ID NCT07435922

Knowledge-focused Sponsor: Healthgen Biotechnology Corp. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study will follow about 2,000 patients who need urgent treatment for low blood protein (hypoalbuminemia) or low blood volume (hypovolemia) and are receiving a plant-based human albumin. Researchers will track side effects and how well the treatment restores albumin levels and blood volume. The goal is to gather real-world safety and effectiveness data, not to test a new drug.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 2,000 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Feb 2026

An estimate. Start dates often move.

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients With Hypoalbuminemia and/or Hypovolemia Requiring Urgent Treatment.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years, male or female. * Hypoalbuminemia and/or hypovolemia requiring urgent treatment. * Agree to participate in this study and sign a written informed consent form by the subject themselves or their legal representative (guardian). * In real-world clinical practice, the attending physician has decided and planned to administer at least one dose of human albumin injection. Exclusion Criteria: * Known allergy to the active ingredients or any excipients of this product. * Any medical condition that, in the investigator's judgment, may significantly increase the subject's risk or interfere with their participation in and completion of this study. * Participation in any other clinical trial of a drug at the time of enrollment in this study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypoalbuminemia are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Hypoalbuminemia Hypovolemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hypoalbuminemia Hypovolemia

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hebei medical university third hosipital

    Shijiazhuang, Hebei, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.